Abstract 209P
Background
Immune-cell indices of immunohistochemistry (IHC) are calculated in countless research studies; often to identify prognostic or predictive biomarkers in cancer patients. The study aimed to investigate how the location of immune cells and the amount of tumor epithelia may affect their calculation in breast cancer (BC) patients whilst exploring multiple sample techniques for IHC immune-cell quantification.
Methods
Formalin-fixed, paraffine-embedded pretreatment tumor tissue (N=227; full-cut slides) from BC patients was stained with two multiplexed chromogenic IHC using CK7/19, CD8, CD4, FOXP3, CD20, CD66b, and CD68. AI-powered image analysis (U-net) determined their area-based indices in the reference spaces: total tumor area, tumor stroma, tumor epithelia, a stromal tumor brim, and a fixed area for each lesion using multiple subsamples (mean no., 100) within tumor stroma (in total, 1 mm2) and epithelia (in total, 1 mm2).
Results
Immune cells were predominantly situated in tumor stroma and rarely epithelia (P<0.01). The most infiltrative cell type was CD68 with a mean index of 3% for epithelia, yet 32% for stroma. In remainder cells, indices were <0.7% for epithelia. The amount of epithelia ranged from 1-60%, which strongly affected index calculations that included the total area of epithelia (P<0.01). In addition, solidity of tumor islands was highly associated with the number of infiltrative CD8, CD66b, and CD68 cells (P<0.01).
Conclusions
The location (stroma vs epithelia) of each immune cell of interest should be considered in connection to its index calculation because the amount of tumor epithelia may skew the result. Alternatively, the novel, unbiased subsampling developed in this study could be used. High solidity meant fewer infiltrating cells, which, conceivably, may affect both prognostic and predictive utility of immune cells.
Legal entity responsible for the study
The authors.
Funding
Danish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract